财务状况与运营风险 - 公司预计将继续在未来一段时间内产生重大净亏损[22] - 公司可能无法成功利用其差异化业务模式构建具有商业价值的产品候选管道[22] - 公司需要大量额外资本来支持其运营，如果无法及时或以可接受的条款筹集到这些资本，可能被迫推迟、减少或取消一个或多个研发项目、未来的商业化努力或其他运营[22] - 公司是一家生物制药公司，运营历史有限，许多开发项目处于早期阶段，这可能使其前景和成功概率难以评估[22] - 公司依赖第三方制造商和供应商，可能导致研发、临床前和临床开发材料的供应受限或中断，或数量和质量不达标[22] - 即使产品候选获得市场批准，也可能无法获得医生、患者、第三方支付方等医疗界必要的商业成功[22] - 产品候选的市场机会可能相对较小，因为潜在患者群体可能不符合或未能对先前治疗产生反应，且目标患者群体的流行率估计可能不准确[22] - 公司依赖第三方进行临床前研究和临床试验，如果这些第三方未能履行合同义务、未能按预期时间完成任务或未能遵守监管要求，公司可能无法获得产品候选的监管批准或商业化[22] - 公司已获得许可的知识产权是通过政府资助项目发现的，因此可能受到联邦法规的限制，如“强制许可”权利、某些报告要求以及对美国本土公司的偏好，这可能限制公司的独家权利和与非美国制造商签订合同的能力[22] - 公司可能面临内部计算机系统或合作方、承包商或顾问的系统故障或安全漏洞，这可能对产品开发计划造成重大干扰[23] 估值与财务模型 - 公司采用Black-Scholes期权定价模型估计股票期权的公允价值，2023年股票期权补偿费用为0.6百万美元，计入一般和管理费用[1011] - 公司使用Monte-Carlo模拟法估值Backstop Put Option Liability和Fixed Maturity Consideration，波动率为100%，预期未来股价范围为$1.95 - $13.93，无风险利率为4.4%[1016] - 2023年可转换票据和SPA认股权证的估值采用Monte-Carlo模拟法，波动率为50%，概率范围为5% - 80%，无风险利率为5.3%[1017] - Ayrton Note Purchase Option的估值采用Black-Scholes Merton模型，波动率为13%，无风险利率为4.4%，截至2023年12月31日，公允价值为零[1018] - 公司采用简化方法确定股票期权的预期期限，无风险利率基于美国国债收益率曲线，预期股息收益率为零[1012] - 公司采用Monte-Carlo模拟法估值2023年可转换票据和SPA认股权证，波动率为100%，概率范围为5% - 80%，无风险利率为3.9%[1017] - 公司采用Black-Scholes Merton模型估值Ayrton Note Purchase Option，波动率为13%，无风险利率为4.4%[1018] - 公司采用简化方法确定股票期权的预期期限，无风险利率基于美国国债收益率曲线，预期股息收益率为零[1012] - 公司采用Monte-Carlo模拟法估值2023年可转换票据和SPA认股权证，波动率为100%，概率范围为5% - 80%，无风险利率为3.9%[1017] - 公司采用Black-Scholes Merton模型估值Ayrton Note Purchase Option，波动率为13%，无风险利率为4.4%[1018] 内部控制与监管风险 - 公司可能无法成功补救现有的或未来的财务报告内部控制中的重大缺陷，影响财务报告的准确性和及时性[1030] - 公司可能无法维持有效的内部控制，导致财务报表重述，影响普通股和认股权证的价格[1031] - 公司可能面临纳斯达克、SEC或其他监管机构的调查，影响运营结果和报告义务[1031]

Ocean Biomedical's Anti-CHI3L1 patent coverage includes multiple methods of use for targeting a broad range of Cancers that include Lung Cancer, Glioblastoma, Prostate Cancer, Melanoma, and Breast Cancer Providence, RI, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that Scientific Co-founder Dr. Jack A. Elias, MD, PhD, and colleagues have published new research in the Journal of Immunology that expands understanding of how CHI3L1 inhibits the body's natural immune response ...

Providence, RI, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that its Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been issued a key U.S. patent for his groundbreaking malaria therapeutic antibody discovery that targets PfGARP. Since publicizing news of his original research on PfGARP and its critical role in the malaria cycle in the Journal NATURE, Dr. Kurtis and his team have been working to deepen their understanding of how it naturally triggers the death of ...

Providence, RI, June 05, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today congratulates its JV partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker presentation highlighting the first-ever human immunogenicity data from its novel checkpoint modifier immunotherapy for HBV functional cure (V ...

Providence, RI, June 05, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today congratulates its JV partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker presentation highlighting the first-ever human immunogenicity data from its novel checkpoint modifier immunotherapy for HBV functional cure (V ...

Providence, RI, May 16, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been granted a new patent for his malaria therapeutic antibody discoveries, targeted to both prevent malaria infection and treat severe malaria. Kurtis' novel approach can cause parasite death at a key stage in the malarial cycle, triggering programmed cell death through apoptosis. This expands patent protection for Dr. Kurtis' novel discoveries at a ti ...

Providence, RI, May 16, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been granted a new patent for his malaria therapeutic antibody discoveries, targeted to both prevent malaria infection and treat severe malaria. Kurtis’ novel approach can cause parasite death at a key stage in the malarial cycle, triggering programmed cell death through apoptosis. This expands patent protection for Dr. Kurtis’ novel discoveries at a ti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40793 OCEAN BIOMEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 87-1309280 55 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Delaware 87-1309280 55 Claverick St., Room 325 Providence, Rhode Island 02903 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share OCEA The NASDAQ Stock Market LLC Warrants, each exercisable for one share of common stock at an exercise price of $11.50 OCEAW The NASDAQ Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURI ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-40793 Ocean Biomedical, Inc. (Exact name of registrant as specified in its charter) | --- | |----------------------- ...